7 months ago

Neuland Laboratories Reports Strong Q2FY26 Growth

Neuland Laboratories Reports Strong Q2FY26 Growth
Neuland Laboratories: What should investors do? · thehindubusinessline.com

Neuland Laboratories is a company that makes special ingredients for medicines.

They have two main parts: one that makes generic ingredients and another that helps other companies test and make their own medicines.

Recently, they had a great quarter with a lot of growth.

Their stock is a bit expensive, but it's because they're doing well in the part that makes more money.

They also have a new facility for making peptides, which are important for proteins.

The company has some debt, but not much, and they're expecting to keep growing.

Investors should watch how their orders and projects are doing because that can change quickly.

Key facts

Company
Neuland Laboratories
Revenue Growth (Q2FY26)
65%
PAT Growth (Q2FY26)
195%
Debt
₹6.6 crore (net)
EBITDA Margins (Generics)
18-22%
Stock Valuation
43 times one-year forward earnings
Innovator Segment Revenue Contribution
93% of H1FY26 revenues
Peptide Facility
2,000-litre large peptide facility expected by FY27

Sources

Related news